The 11th World Clinical Biomarkers & CDx Summit returns in 2021 as the only end-to-end industry-led meeting diving deep into the science of transitioning biomarkers to the clinic, their clinical validation and later commercialization with a CDx.
With over half of drugs approved by the FDA now supported by a biomarker and as new CDx collaborations are announced on an almost weekly basis, demand for diagnostic tools enabling earlier, more precise, therapeutic interventions is at an all time high. Join with 1000+ key stakeholders across biomarker, translational, clinical, regulatory and commercial functions to tackle end-to-end challenges and deliver game-changing drug-Dx products to market.
Across 2 days of comprehensive content, 65+ global expert speakers will share fresh data paired with inspiring stories from innovative partnership collaborations to help you overcome your most pressing challenges and accelerate curative medicine for heterogeneous patient populations.
With 3-tracks addressing the entire lifecycle of biomarker-driven drug development, explore biomarkers and Dx movement within bioanalytical analysis, AI/ML application, data sharing and the regulatory and payer landscape. Covering immune-oncology, neurodegenerative, metabolic, autoimmune and rare indications, gain a diverse picture of today’s expanding personalized medicine ecosystem.
This is your unmissable event, bringing you the tools, insights and techniques to design a clinically robust biomarker and commercially competitive CDx!
Price: USD 0.00
Speakers: Christopher Conn Director, Companion Diagnostics Strategy Lead AbbVie, Charles Koyias Associate Director, Global Medical Affairs, Oncology AbbVie, Tom Defay Deputy Head, Diagnostics Strategy & Development Alexion Pharmaceuticals, Inc., Darren Hodgson Global Project Leader & Site Head Translational Medicine AstraZeneca Oncology, Janelle Schrag Assistant Director, Research Programs Association of Community Cancer Centers, Chowdary Dondapati Executive Director, Head of CDx Marketing (US) Bayer Oncology, Michael Kiebish Chief Precision Medicine Officer BERG, Chris Whelen Associate Director & Head of Translational Genetics Biogen, Krystin Meidell Associate Director, Global RegCMC Device Lead Biogen, Lakshmi Amaravadi Vice President, Head of Translational Medicine Boston Pharmaceuticals, Kashyap Patel President Community Oncology, Alessandra Cesano Chief Medical Officer ESSA Pharma, Mark Stuart Vice President, Science Policy Friends of Cancer Research, Roman Yelensky Executive Vice President & Chief Technology Officer Gristone Bio, Antonella Cardone Executive Director European Cancer Patient Coalition, Jaya Krishnan Co-Founder Genome Biologics, Christine Blinco Global Director of Marketing, Oncology Diagnostics GlaxoSmithKline, Ellie Corigliano Head of CDx Cell & Gene Therapies Oncology GlaxoSmithKline, Patrick Ng Associate Director of Translational Medicine Harpoon Therapeutics, Stephane Wong Immuno-Oncology Companion Diagnostics Senior Director GlaxoSmithKline, Eugean Jiwanmall Senior Research Analyst for Medical Policy & Technology Evaluation Independence Blue Cross, Andrea Stevens Global CoDx Market Access Director Janssen Inc., Johan Baeck Senior Vice President Clinical Development & Medical Affairs Jounce Therapeutics, Nikki Martin Director, Precision Medicine Initiatives LUNGevity, Travis Hollman Dermatopathologist Memorial Sloan Kettering Cancer Center, Joshua Xu Branch Chief, National Center for Toxicological Research US Food & Drug Administration, Jennifer Dacpano- Komansky Director, Global Regulatory Affairs, Medical Devices Novartis, Jörg Engelbergs Scientific-Regulatory Expert Targeted & Personalized Biomedicines Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines (National Competent Authority responsible for Biomedicines), Danielle Murphy Director, Translational Oncology Pfizer, Jeffrey Kovacs Group Leader MD Anderson Cancer Center, Markus Zettl Senior Director of Immuno–Oncology Pieris Pharmaceuticals GmbH, Shane Olwill Senior Vice President, Head of Translational Science Pieris Pharmaceuticals GmbH, Ming Sound Tsao Professor & Senior Scientist Princess Margaret Cancer Centre, University Health Network, Javier Perez Director, Precision Medicine, Companion Diagnostics Regeneron Pharmaceuticals, Brian Baker Senior Director, Regulatory Affairs (CDx) Regeneron Pharmaceuticals, Katherine Block Director, Biomarker Sciences Sangamo Therapeutics, David Portman Chief Executive Officer, Chief Medical Officer Sermonix Pharmaceuticals, Gary Riordan CDx Regulatory Consultant Sermonix Pharmaceuticals, Arunthi Thiagalingam Director, Pharmacology/ Translational Medicine Spectrum Pharmaceuticals, Qing Kang-Fortner Associate Director - Translational Medicine Syros Pharmaceuticals, Kaye Foster Senior Advisor & Executive Coach The Boston Consulting Group (BCG), Michael Fossel President & Founder Telocyte, Jonathan Levenson Vice President, Translational Biology Tiaki Therapeutics, Jeanine Roodhart Oncology Specialist UMC Utrecht, Michele Vendruscolo Chief Scientific Officer University of Cambridge & Wren Therapeutics, Jude O’Donnell Head, Regulatory Strategy Almac Diagnostic Services, Xiaolei Xu Director, Global Regulatory Affairs, Companion Diagnostics Agilent Technologies, Courtney Nicholson Director Business Development Abcam, Gavin Gordon Vice President, Clinical Market Development Akoya Biosciences, Rudi Powels Founder Director, Chief Executive Officer Biocartis, Gary Pestano Chief Development Officer Biodesix, Joseph Ferrara President & Chief Executive Officer Boston Healthcare, Tom Li Head of Global Biopharma Business Development Burning Rock Biotech, Mark Roberts Senior Director, Diagnostics Development Covance by Labcorp, Rick Wenstrup Chief Medical Officer Epic Sciences, Elena Helman Head, BioPharma Bioinformatics Guardant Health, Corrinne Danan Executive Vice President, Partnerships Business Unit HalioDx, Matt Nelson Senior Director of Business Development CDx Illumina, Hartmut Juhl Founder & Chief Executive Officer Indivumed, Tim Forshew Head of Science and Innovation & Co-Founder Inivata, Olga Colgan Global Marketing Director, Advances Staining & Imaging Leica Biosystems, Andy Hadd Director of Regulatory Affairs Natera, Scott Reid Executive Director, Strategic Alliances & CDx NeoGenomics Laboratories, Andrew Beck Co-Founder & Chief Executive Officer Path AI, Kedar Hastak Senior Field Applications Scientist Personalis, John McAuliffe Senior Director, CDx Partnering Roche Molecular Solutions, Russell Garlick Chief Scientific Officer Seracare, Lauren Silvis Senior Vice President, External Affairs Tempus, Luca Quagliata Vice President, Global Head of Medical Affairs Thermo Fisher Scientific, Keith Wharton Vice President, Medical Director Ultivue
Time: On Wednesday September 29, 2021 at 8:00 am (ends Thursday September 30, 2021 at 6:00 pm)